Arterial Thrombosis - Pipeline Review, H1 2015

Published: Feb, 2015 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Arterial Thrombosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Arterial Thrombosis - Pipeline Review, H1 2015', provides an overview of the Arterial Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Arterial Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arterial Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Arterial Thrombosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Arterial Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Arterial Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Arterial Thrombosis Overview 7
Therapeutics Development 8
Pipeline Products for Arterial Thrombosis - Overview 8
Pipeline Products for Arterial Thrombosis - Comparative Analysis 9
Arterial Thrombosis - Therapeutics under Development by Companies 10
Arterial Thrombosis - Therapeutics under Investigation by Universities/Institutes 11
Arterial Thrombosis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Arterial Thrombosis - Products under Development by Companies 15
Arterial Thrombosis - Products under Investigation by Universities/Institutes 16
Arterial Thrombosis - Companies Involved in Therapeutics Development 17
Arena Pharmaceuticals, Inc. 17
Astellas Pharma Inc. 18
AstraZeneca PLC 19
Bayer AG 20
Bristol-Myers Squibb Company 21
Eisai Co., Ltd. 22
Sanofi 23
Arterial Thrombosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AS-1468240 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ASP-1645 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ASP-6537 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BAY-1213790 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BMS-593214 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
C-3 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-5539 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ER-410660 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Ichorcumab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PZ-128 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SAR-216471 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
temanogrel hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ticagrelor - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Arterial Thrombosis - Recent Pipeline Updates 49
Arterial Thrombosis - Dormant Projects 54
Arterial Thrombosis - Product Development Milestones 55
Featured News & Press Releases 55
Nov 13, 2014: AstraZeneca announces initiation of development programme for BRILINTA reversal agent 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables
Number of Products under Development for Arterial Thrombosis, H1 2015 8
Number of Products under Development for Arterial Thrombosis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Arterial Thrombosis - Pipeline by Arena Pharmaceuticals, Inc., H1 2015 17
Arterial Thrombosis - Pipeline by Astellas Pharma Inc., H1 2015 18
Arterial Thrombosis - Pipeline by AstraZeneca PLC, H1 2015 19
Arterial Thrombosis - Pipeline by Bayer AG, H1 2015 20
Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 21
Arterial Thrombosis - Pipeline by Eisai Co., Ltd., H1 2015 22
Arterial Thrombosis - Pipeline by Sanofi, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Arterial Thrombosis Therapeutics - Recent Pipeline Updates, H1 2015 49
Arterial Thrombosis - Dormant Projects, H1 2015 54